Department of Epidemiology, University of Washington, Seattle, Washington.
Kidney Research Institute, Seattle, Washington.
J Am Soc Nephrol. 2021 Feb;32(2):459-468. doi: 10.1681/ASN.2020060833. Epub 2020 Nov 25.
Although proximal tubular secretion is the primary mechanism of kidney drug elimination, current kidney drug dosing strategies are on the basis of eGFR.
In a dedicated pharmacokinetic study to compare GFR with tubular secretory clearance for predicting kidney drug elimination, we evaluated stable outpatients with eGFRs ranging from 21 to 140 ml/min per 1.73 m. After administering single doses of furosemide and famciclovir (metabolized to penciclovir), we calculated their kidney clearances on the basis of sequential plasma and timed urine measurements. Concomitantly, we quantified eight endogenous secretory solutes in plasma and urine using liquid chromatography-tandem mass spectrometry and measured GFR by iohexol clearance (iGFR). We computed a summary secretion score as the scaled average of the secretory solute clearances.
Median iGFR of the 54 participants was 73 ml/min per 1.73 m. The kidney furosemide clearance correlated with iGFR (=0.84) and the summary secretion score (=0.86). The mean proportionate error (MPE) between iGFR-predicted and measured furosemide clearance was 30.0%. The lowest MPE was observed for the summary secretion score (24.1%); MPEs for individual secretory solutes ranged from 27.3% to 48.0%. These predictive errors were statistically indistinguishable. Penciclovir kidney clearance was correlated with iGFR (=0.83) and with the summary secretion score (=0.91), with similar predictive accuracy of iGFR and secretory clearances. Combining iGFR with the summary secretion score yielded only modest improvements in the prediction of the kidney clearance of furosemide and penciclovir.
Secretory solute clearance measurements can predict kidney drug clearances. However, tight linkage between GFR and proximal tubular secretory clearance in stable outpatients provides some reassurance that GFR, even when estimated, is a useful surrogate for predicting secretory drug clearances in such patients.
尽管近端肾小管分泌是肾脏药物消除的主要机制,但目前的肾脏药物剂量策略是基于 eGFR。
在一项专门的药代动力学研究中,我们比较了肾小球滤过率 (GFR) 与管状分泌清除率,以预测肾脏药物消除,该研究纳入了 eGFR 范围在 21 至 140 ml/min/1.73 m² 的稳定门诊患者。在给予单剂量呋塞米和泛昔洛韦(代谢为喷昔洛韦)后,我们根据连续的血浆和定时尿液测量来计算它们的肾脏清除率。同时,我们使用液相色谱-串联质谱法测量了血浆和尿液中的 8 种内源性分泌溶质,并通过碘海醇清除率(iGFR)来测量 GFR。我们计算了一个综合分泌评分,作为分泌溶质清除率的比例平均值。
54 名参与者的中位 iGFR 为 73 ml/min/1.73 m²。肾脏呋塞米清除率与 iGFR(=0.84)和综合分泌评分(=0.86)相关。iGFR 预测与实测呋塞米清除率之间的平均比例误差(MPE)为 30.0%。综合分泌评分的 MPE 最低(24.1%);各分泌溶质的 MPE 范围为 27.3%至 48.0%。这些预测误差在统计学上无显著差异。喷昔洛韦肾脏清除率与 iGFR(=0.83)和综合分泌评分(=0.91)相关,iGFR 和分泌清除率的预测准确性相似。将 iGFR 与综合分泌评分结合使用,仅能适度提高呋塞米和喷昔洛韦肾脏清除率的预测能力。
分泌溶质清除率测量可预测肾脏药物清除率。然而,稳定门诊患者中 GFR 与近端肾小管分泌清除率之间的紧密联系,为 GFR 即使是估计值,也是预测此类患者分泌性药物清除率的有用替代指标提供了一些保证。